UMN Pharma’s Avian Flu Vaccine Trial Confirms Efficacy and Safety
This article was originally published in PharmAsia News
Executive Summary
Akita based UMN Pharma announced that a clinical trial conducted in 2008 on 125 healthy males aged 20 to 40 in Tokyo confirmed efficacy and safety of UMN-0501, a H5N1 type avian flu vaccine. The company will release the details of the trial result at the World Health Organization's avian flu conference in February. UMN Pharma also plans to start a new trial for the flu vaccine with added effective ingredients within the year. UMN-0501 has been designated an orphan drug in Japan and the company receives assistance to cover development expenses. (Click here for more - Japanese language
You may also be interested in...
Chinese Firms Up Their Game In Novel Flu Antiviral Development
Joincare Pharmaceutical and partner TaiGen Biotechnology tout preliminary Phase III results in uncomplicated acute influenza for TG-1000, a homegrown follower of Shionogi/Roche’s oral antiviral Xofluza. Novel antivirals for flu were hotly pursued by Chinese developers throughout 2023.
Quotable: Words Of Wisdom From Our Recent APAC Coverage
Scrip's APAC team selects notable quotes from recent interviews, conferences and other coverage to highlight the views of senior executives and officials on the major topics facing the biopharma sector in the region.
Generic Or Innovator? Sandoz Sues CMS Over Potential Change In Rebate Classification
Sandoz argued against paying higher rebates for two of its drugs via the Centers for Medicare and Medicaid Services’ Medicaid drug rebate program in a US court six years after the suggestion was first made.